

European Association for the
Study of Diabetes (EASD) 2025


Post-Conference Survey

Are you interested to hear what
Healthcare Professionals were
most interested in?

Swipe to see the results



Novo Nordisk and Eli Lilly generated the most excitement at EASD 2025



Which companies were you most excited to hear about at EASD 2025?
Please rank your top 3 companies in order of excitement, with 1 being the company you were most excited about.

Source: Adelphi Research, post-EASD online global study n=59 HCPs.

Sessions around GLP-1 developments and SURPASS had the highest engagement

71%

• GLP-1 trending: the latest developments

64%

Comparison of TIRZEPATIDE and dulaglutide on major adverse cardiovascular events in participants with type 2 diabetes and atherosclerotic cardiovascular disease: SURPASS-CVOT

64%

TIRZEPATIDE: Breaking barriers in weight management, Type 2 Diabetes, and OSA

63%

Effect of smoking status on once weekly semaglutide 1 mg treatment in people with peripheral artery disease and type 2 diabetes: a secondary analysis of the STRIDE trial

63%

• Is semaglutide taking a step up?


How engaging were the following sessions at EASD 2025?

Top 2 selection (6-7), 'extremely engaging'. Rating question: scale 1 to 7 where 1 is 'not at all engaging' and 7 is 'extremely engaging'.

Source: Adelphi Research, post-EASD online global study n=59 HCPs.




Mounjaro created the highest excitement at EASD 2025, closely followed by semaglutide brands



Which of the following products were you most excited to learn about at EASD 2025? Please rank your top 3 products in order of excitement, with 1 being the product you were most excited about.

Source: Adelphi Research, post-EASD online global study n=59 HCPs.

Attendees were most interested in learning about T2D, obesity, MASH and CVD



Which of the following disease states were you most interested in at EASD 2025?
Please rank your top 3 disease states in order of interest, with 1 being the disease state you were most interested in.

Source: Adelphi Research, post-EASD online global study n=59 HCPs.



SURPASS trials created the highest interest, followed by PIONEER and FLOW

37% - SURPASS

32% - SURPASS- CVOT

29% - SURPASS-PEDS

22% - PIONEER

22% - FLOW

*Which of the following clinical trials were you most interested in at EASD 2025?
Please rank your top 3 clinical trials in order of interest, with 1 being the clinical trial you were most interested in.*

Source: Adelphi Research, post-EASD online global study n=59 HCPs.



If you would like to
learn more, reach out to

Ben.Walker@omc.com (UK)
Amy.Gilpin@omc.com (US)



**DIABETES &
METABOLIC
TASK FORCE**